No reliable human safety profile has been established through controlled clinical development
With ongoing treatment, other, more serious side effects can emerge
GLP-1 GLP-1GIP/GLP-12 GLP-1GIP/GLP-1 GLP-1 GLP-1Glucagon-Like Peptide-1-1 : GLP-1 : GLP-1 : GLP-1 : GLP-1 GLP-1GLP-1 GLP-1 11112 1130 GIP/GLP-1 GIP/GLP-1GLP-1GIPGastric Inhibitory Polypeptide GIPGLP-12GIPGIP GIP GIP GIPGLP-1 2023GIP/GLP-1 SURPASS 4015 mg/HbA1c29.5 kg GLP-1HbA1c GLP-1 GLP-1GIP/GLP-10 GLP-12 GLP-11.271.361.55 13GLP-11.5GLP-1 GLP-1GIP/GLP-12 MazdutideGLP-12Mazdutide2HbA1c20HbA1c1.67%7.1% GIPGLP-13 Retatrutide12 mg/24HbA1c2%3617%Retatrutide481 mg8.74 mg17.18 mg22.812 mg24.21/4 GLP-1GIP Nauck MA, Quast DR, Wefers J, Pfeiffer AFH
Del Giudice et al
Aquat Toxicol 9:91103 Ankley GT, Bennett RS, Erickson RJ, Hoff DJ, Hornung MW, Johnson RD, Mount DR, Nichols JW, Russom CL, Schmieder PK, Serrano JA, Tietge JE, Villeneuve DL (2010) Adverse outcome pathways: a conceptual framework to support ecotoxicology research and risk assessment
Panamas licensed psychiatrists and clinical neuropsychologists apply these same criteria
